News coverage about Veracyte (NASDAQ:VCYT) has been trending positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Veracyte earned a coverage optimism score of 0.33 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.7466713729572 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Veracyte Unveils Afirma Xpression Atlas Platform at ENDO 2018 (finance.yahoo.com)
- Veracyte Announces New Data Suggesting Afirma GSC’s Ability to Help Significantly More Patients Avoid Unnecessary Thyroid Surgery (finance.yahoo.com)
- Veracyte Inc (VCYT) Expected to Announce Quarterly Sales of $18.31 Million (americanbankingnews.com)
- Veracyte (VCYT) Says New Data Demonstrating Real-World Performance of Afirma GSC to Be Presented at ENDO (streetinsider.com)
- Q1 2018 EPS Estimates for Veracyte Inc Lowered by Analyst (VCYT) (americanbankingnews.com)
A number of analysts have recently commented on VCYT shares. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $5.40 price target on shares of Veracyte in a research report on Thursday, March 1st. ValuEngine lowered Veracyte from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research lowered Veracyte from a “hold” rating to a “sell” rating in a research report on Tuesday, March 6th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Veracyte presently has an average rating of “Hold” and a consensus target price of $10.78.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by BBNS and is owned by of BBNS. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://baseballnewssource.com/2018/03/22/veracyte-vcyt-earns-media-impact-score-of-0-33/1925031.html.
Veracyte Company Profile
Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.